Diabetic Retinopathy Market Growth, Future Prospects and Competitive Analysis, 2016-2022, the global diabetic retinopathy market was valued at USD 7.9 Bn in 2015, and is expected to reach USD 12.6 Bn by 2022, expanding at a CAGR of 6.7% from 2016 to 2022.
Browse Full Report Visit – http://www.acutemarketreports.com/report/diabetic-retinopathy-market
Perpetual growth in the prevalence of diabetes in middle- and low-income countries and further anticipation of future rise indicates the growth in prevalence of diabetic related complications, and hence diabetic retinopathy. Diabetic retinopathy is among the key causes of legal blindness in working adult population. With overall prevalence of around 34% in the total diabetes population, the burden in form of direct and indirect management cost of diabetic retinopathy is humongous. Treatment for diabetic retinopathy is determined upon the severity of condition, where non-proliferative diabetic retinopathy is excuses from treatment.
Along with high prevalence of diabetes and hence diabetic retinopathy, wide availability of treatment options also serve as key drivers of this market. At present, diabetic retinopathy is mostly treated with laser treatment and vitrectomy. As the prevalence of macular edema in diabetic retinopathy is on rise, it is anticipated that the demand for treatment drugs and injections will steadily grow. Rise in healthcare expenditure is another key contributor to the growth of diabetic retinopathy market. However, the market growth may be shunted due to shortage of skilled professional for treating diabetes and related complications. The key diabetic retinopathy treatment drugs studied in this report are Aflibercept (Eylea), Bevacizumab (Avastin), Fluocinolone acetonide (Iluvien), Ranibizumab (Lucentis) and Triamcinolone acetonide.
Geographically, this report studies the diabetic retinopathy for North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America markets. These regions are further split into key country-level markets that determine the overall trends in respective regional market. Among the considered geographies, North America and Europe together take over 50% of the global market share for diabetic retinopathy treatments. High awareness, early introduction of breakthrough treatment devices and drugs, extensive research initiatives being taking place in the U.S. and Western Europe and favorable reimbursements are the key factors that contribute to the dominance of these regions.
Phenomenal rise in prevalence of diabetes in India, China and other middle- and low-income countries of Asia-Pacific and Middle East and Africa make these regions the fastest growing geographical markets during the forecast period. Other drivers of diabetic retinopathy market in Asia-Pacific and Middle East and Africa markets are rapid development of healthcare infrastructure, growing focus of market players to develop their foothold in Asia and Middle East markets, and growing government and non-government initiatives for developing awareness about diabetes management in the general population.
To Get Complete Report @ http://www.acutemarketreports.com/report/diabetic-retinopathy-market
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
Chapter 2 Executive Summary
2.1 Diabetic Retinopathy Treatment Devices Market, by Type, 2015 (USD Mn)
2.2 Diabetic Retinopathy Treatment Drugs Market, by Type, 2015 (USD Mn)
2.3 Diabetic Retinopathy Market Share, by Geography, 2015 (Value %)
Chapter 3 Diabetic Retinopathy Market: Market Dynamics and Outlook
3.2 Diabetic Retinopathy: Facts and Figures
3.5 Future Prospects
3.6 Attractive Investment Proposition
3.1 Competitive Analysis: Market Positioning, by Key Market Players
Chapter 4 Global Diabetic Retinopathy Treatment Devices Market Analysis, by Device Type, 2014-2022 (USD Mn)
4.2 Focal Laser Treatment
4.3 Scatter Laser Treatment
4.4 Vitrectomy Devices
Chapter 5 Global Diabetic Retinopathy Drugs Market Analysis, by Drug Type, 2014-2022 (USD Mn)
5.2 Aflibercept (Eylea)
5.3 Bevacizumab (Avastin)
5.4 Fluocinolone Acetonide (Iluvien)
5.5 Ranibizumab (Lucentis)
5.6 Triamcinolone Acetonide Injection
Chapter 6 Global Diabetic Retinopathy Market, by Geography, 2014-2022 (USD Mn)
6.2 North America
6.3.3 Rest of Europe
6.4.3 Rest of Asia-Pacific
6.5 Middle East and Africa (MEA)
6.6 Latin America
Chapter 7 Company Profiles
7.1 Alimera Sciences, Inc
7.1.1 Business Description
7.1.2 Financial Health and Budget Allocation
7.1.3 Product Positions/Portfolio
7.1.4 News Coverage
7.2.1 Business Description
7.2.2 Financial Health and Budget Allocation
7.2.3 Product Positions/Portfolio
7.2.4 News Coverage
7.3 Genentech USA, Inc.
7.3.1 Business Description
7.3.2 Financial Health and Budget Allocation
7.3.3 Product Positions/Portfolio
7.3.4 News Coverage
7.4 Sandoz Inc.
7.4.1 Business Description
7.4.2 Financial Health and Budget Allocation
7.4.3 Product Positions/Portfolio
7.4.4 News Coverage
7.5 Bayer Pharma AG
7.5.1 Business Description
7.5.2 Financial Health and Budget Allocation
7.5.3 Product Positions/Portfolio
About – Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Browse All Reports of This Category – http://www.acutemarketreports.com/category/market-research
Website : http://www.acutemarketreports.com
Our Blog :- http://www.pdfdevices.com/
Company Name: Acute Market Reports
Contact Person: Chris Paul
Phone: India: +91 7755981103, Toll Free US/Canada: +1-855-455-8662
Address:Office No 01, 1st Floor, Aditi Mall, Baner